LONDON – Virttu Biologics Ltd. hired biotech veteran Steven Powell as CEO, with a brief to reshape strategy and turbo-charge efforts to commercialize oncolytic virus Seprehvir, a broad-spectrum product that has yet to reach the advanced stages of clinical development despite having been tested in more than 75 patients, in a number of solid tumors.